Our Sponsors | NFXF (original) (raw)

Skip to content

Our Sponsors

Our SponsorsDan Whiting2024-09-30T19:34:48-04:00

Our Corporate Sponsors

Corporate sponsors assist the National Fragile X Foundation by supporting our current programs and new initiatives across all strategic initiatives — advocacy, education, treatment, and research.

Our Corporate Sponsors

Corporate sponsors assist the National Fragile X Foundation by supporting our current programs and new initiatives across all strategic initiatives — advocacy, education, treatment, and research.

Meet Our 2024 Sponsors

Harmony Biosciences logo, an NFXF sponsor.

Harmony Biosciences

Harmony Biosciences specializes in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that when empathy and innovation meet, a better life can begin for people living with neurological diseases. Zynerba Pharmaceuticals is now part of Harmony Biosciences which expands Harmony’s pipeline with a product candidate that could address rare neuropsychiatric disorders including Fragile X syndrome.

Tetra Therapeutics logo, an NFXF sponsor.

Tetra Therapeutics

Tetra Therapeutics, a Shionogi Group Company, is focused on developing treatments for central nervous system diseases and disorders with a lead program in Fragile X syndrome (FXS). Shionogi acquired Tetra in 2020 as part of its mission to develop medications for unmet medical needs and to contribute meaningfully to society. Shionogi and Tetra are researching an investigational treatment called zatolmilast for FXS. The U.S. Food & Drug Administration has granted zatolmilast Orphan Drug Designation, Rare Pediatric Disease Designation and Fast Track Designation. If approved, zatolmilast could offer people living with FXS the first cognitive treatment developed specifically for them. Learn about their research and find out more about the eligibility criteria to join their study here.

Kaerus Bioscience logo, an NFXF sponsor.

Kaerus Bioscience

Kaerus is developing targeted therapeutics that address an underlying ion channel dysfunction in Fragile X syndrome that contributes to hyper-excitability of the central nervous system in these patients. Our unique mechanistic approach to targeting BK channels has enabled Kaerus to expand focus on other rare genetic syndromes linked to the KCNMA1 gene.

Anavex Life Sciences logo

Anavex

Anavex Life Sciences Corp is working to develop novel small molecule treatments for some of the most challenging central nervous system (CNS) diseases facing society today, including Alzheimer’s, Parkinson’s, Rett syndrome, and other rare diseases.

Spinogenix, NFXF corporate sponsor

Spinogenix

Spinogenix is pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide.

Visibility

Sponsors have their name in front of thousands of households who engage with our content each day.

Recognition

Sponsors get brand recognition at NFXF annual national and international events and online tools.

Relevancy

Sponsors engage as a relevant part of the Fragile X community through NFXF programming.

Kristin Bogart

Interested in learning more about our Corporate Sponsorship program?

If you have questions, we’d love to hear from you! You can reach out to Kristin Bogart directly, or submit your question or comment through our contact form.